Literature DB >> 7835856

A mental health capitation program: II. Cost-benefit analysis.

S K Reed1, K D Hennessy, O S Mitchell, H M Babigian.   

Abstract

OBJECTIVE: Total monetized and nonmonetized costs and benefits to society of the Monroe-Livingston demonstration project's capitated payment system (CPS) were analyzed.
METHODS: Total costs and benefits of care for individuals who were prerandomized to an experimental group (of whom about 57 percent were enrolled in the CPS) were compared with those for a control group who received traditional fee-for-service care. Separate two-year results are presented for continuous patients, who were enrolled in a comprehensive CPS plan (N = 201) and for intermittent patients, who were enrolled in a partial plan (N = 155).
RESULTS: All groups showed improvements on many psychosocial measures over the two years. Continuous patients in the experimental group experienced less hospitalization, more case management and transportation services, and higher levels of victimization and were more likely to live in unsupervised settings than continuous patients in the control group. Total annual per patient costs for care of continuous patients ranged from $74,000 to more than $100,000, largely reflecting differences in rates of hospitalization. Experimental subjects in the partial capitation condition differed from the control group in this plan on fewer measures; both groups reported high levels of case management and social support services and relatively lower levels of supervised housing.
CONCLUSIONS: The CPS resulted in major improvements in the community's services for persons with serious mental illness and reduced the proportion of care provided in the state hospital.

Entities:  

Mesh:

Year:  1994        PMID: 7835856     DOI: 10.1176/ps.45.11.1097

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


  9 in total

1.  Outcomes for Medicaid beneficiaries with schizophrenia under a prepaid mental health carve-out.

Authors:  W G Manning; C F Liu; T J Stoner; D Z Gray; N Lurie; M Popkin; J B Christianson
Journal:  J Behav Health Serv Res       Date:  1999-11       Impact factor: 1.505

2.  Effects of capitation on health of the chronically ill. Implications for antipsychotic drug therapy.

Authors:  S K Reed; K Maharaj
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

3.  A capitated model for a cross-section of severely mentally ill clients: hospitalization.

Authors:  D Chandler; J Meisel; T Hu; M McGowen; K Madison
Journal:  Community Ment Health J       Date:  1998-02

4.  Two-year outcomes of fee-for-service and capitated medicaid programs for people with severe mental illness.

Authors:  Brian J Cuffel; Joan R Bloom; Neal Wallace; Jaclyn W Hausman; Teh-wei Hu
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

5.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Authors:  S H Hamilton; D A Revicki; E T Edgell; L A Genduso; G Tollefson
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

6.  Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Authors:  E T Edgell; S W Andersen; B M Johnstone; B Dulisse; D Revicki; A Breier
Journal:  Pharmacoeconomics       Date:  2000-12       Impact factor: 4.981

7.  Benefits and costs of supported employment from three perspectives.

Authors:  R E Clark; H Xie; D R Becker; R E Drake
Journal:  J Behav Health Serv Res       Date:  1998-02       Impact factor: 1.505

8.  Mental health costs and access under alternative capitation systems in Colorado.

Authors:  Joan R Bloom; Teh-Wei Hu; Neal Wallace; Brian Cuffel; Jaclyn W Hausman; Mei-Ling Sheu; Richard Scheffler
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

9.  Mental health costs, other public costs, and family burden among mental health clients in capitated integrated service agencies.

Authors:  D Chandler; T W Hu; J Meisel; M McGowen; K Madison
Journal:  J Ment Health Adm       Date:  1997
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.